Publication Type:

Journal Article


Molecular Pharmaceutics, Volume 10, Number 11, p.4159-4167 (2013)



alkaline phosphatase, animal experiment, article, biocompatibility, calcium cell level, cell proliferation, chitosan, controlled study, cross reaction, drug bioavailability, female, gastrointestinal transit, human, human cell, in vitro study, in vivo study, infrared spectroscopy, light scattering, limit of detection, macrogol 200, nanoencapsulation, nanoparticle, nonhuman, osteoblast, osteocalcin, osteoporosis, parathyroid hormone[1-34], particle size, priority journal, rat, scanning electron microscopy, static electricity, surface charge, transmission electron microscopy, zeta potential


Oral formulation of human parathyroid hormone 1-34 (PTH 1-34) is an alternative patient compliant route in treating osteoporosis. PTH 1-34 loaded chitosan nanoparticles were PEGylated (PEG-CS-PTH NPs) and characterized by DLS, SEM, TEM and FTIR. PEG-CS-PTH NP aggregates of 200-250 nm which in turn comprised 20 nm individual nanoparticles were observed in SEM and TEM images respectively. The PEG-CS-PTH NP with 40% encapsulation efficiency was subjected to an in vitro release in simulated rat body fluids. PEG-CS-PTH NP treated human primary osteoblast cells, upon PTH 1-34 receptor activation, produced second messenger-cAMP, which downstream stimulated intracellular calcium uptake, production of bone specific alkaline phosphatase, osteocalcin etc., which substantiates the anabolic effect of the peptide. PEG-CS-PTH NPs showed an oral bioavailability of 100-160 pg/mL PTH 1-34 throughout 48 h, which is remarkable compared to the bare PTH 1-34 and CS-PTH NPs. The NIR image of gastrointestinal transit of ICG conjugated PEG-CS-PTH NPs supports this significant finding. © 2013 American Chemical Society.


cited By (since 1996)0

Cite this Research Publication

D. Narayanan, Anitha, A., Dr. Jayakumar Rangasamy, and Chennazhi, K. P., “In vitro and in vivo evaluation of osteoporosis therapeutic peptide PTH 1-34 loaded PEGylated chitosan nanoparticles”, Molecular Pharmaceutics, vol. 10, pp. 4159-4167, 2013.